cjc 1295 ipamorelin stack: Frequently asked questions

Transient fluid retention in weeks 1-3 is normal. Growth hormone transiently increases aldosterone activity and sodium reabsorption in the kidneys. This resolves as the body adapts to elevated GH levels. If retention persists beyond week 4 or causes significant discomfort, reduce Ipamorelin dose to 100-150mcg nightly while maintaining CJC-1295 at 200mcg. Persistent edema suggests either excessive dosing or underlying insulin resistance that GH is unmasking.

CJC-1295's extended half-life provides buffer. Missing 1-2 Ipamorelin doses won't derail progress. If you miss more than 3 consecutive nightly injections, resume at your regular dose on the next scheduled day. Do not double-dose to compensate. Missing an entire week resets the hormonal adaptation curve by approximately 10 days. You'll need to extend the protocol by 1-2 weeks to achieve equivalent outcomes.

Discard it immediately. Properly reconstituted CJC-1295 and Ipamorelin are clear to slightly opalescent. Cloudiness indicates protein aggregation from temperature damage, contamination, or expired product. Injecting aggregated peptides risks immune response without therapeutic benefit. This is why peptide sourcing matters: Real Peptides maintains cold chain integrity through synthesis, shipping, and storage to prevent the thermal excursions that cause degradation.

Continue the protocol. Initial body composition changes lag behind hormonal shifts by 3-4 weeks. Growth hormone's lipolytic effect requires time to upregulate hormone-sensitive lipase expression and shift substrate utilisation away from glucose oxidation. If the scale hasn't moved by week 6 despite caloric deficit and consistent dosing, verify peptide reconstitution technique and storage temperature compliance. The most common issue isn't the peptides. It's untracked caloric intake offsetting the metabolic boost.

Use the CJC-1295/Ipamorelin stack administered 30–60 minutes before sleep. This timing synchronises exogenous GH pulses with the endogenous nocturnal surge, preserving circadian rhythm rather than overriding it. MK-677's continuous elevation disrupts normal pulsatility, which matters for studies examining downstream signaling cascades (mTOR, AMPK, STAT5) that respond differently to pulsatile versus sustained GH exposure. If your endpoints involve receptor sensitivity or feedback loop integrity, pulsatile dosing is the only physiologically valid approach.

For MK-677 protocols, water retention peaks in weeks 2–4 and typically resolves by week 6–8 as aldosterone signaling adapts. If fluid accumulation is confounding DEXA or bioimpedance measurements, delay body composition endpoints until week 8 or use the CJC/Ipamorelin stack instead. Incidence of noticeable retention drops to under 15% with pulsatile dosing. Subcutaneous fluid doesn't reflect true lean mass changes, so imaging modalities (MRI, CT) provide more accurate differentiation than bioimpedance during the adaptation window.

Reduce the dose to 10mg daily or split administration into 5mg twice daily (morning and evening). The appetite effect is dose-dependent. Lower doses still produce measurable IGF-1 elevation (20–40% above baseline) while reducing ghrelin-mediated hunger signaling. If appetite stimulation remains protocol-limiting, transition to the CJC/Ipamorelin stack, which avoids orexigenic pathways entirely. Document the transition timing and run IGF-1 sampling at week 1 post-switch to confirm therapeutic levels are maintained.